TY  - CONF 
AU  - Califano, R
AU  - Hochmair, M J
AU  - Gridelli, C
AU  - Delmonte, A
AU  - García Campelo, María del Rosario
AU  - Bearz, A
AU  - Griesinger, F
AU  - Morabito, A
AU  - Felip, E
AU  - Ghosh, S
AU  - Tiseo, M
AU  - Haney, J
AU  - Kerstein, D
AU  - Popat, S
AU  - Camidge, D R
PY  - 2019
SN  - 0923-7534
UR  - http://hdl.handle.net/20.500.11940/15944
AB  - Background: We report results of the first interim analysis (IA) from the ALTA-1L study of BRG vs CRZ in anaplastic lymphoma kinase (ALK) inhibitor–naive, ALK-positive non–small cell lung cancer (ALK+ NSCLC; NCT02737501).

Methods: This open-label,...
LA  - eng
TI  - Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
DO  - 10.1093/annonc/mdz063.004
KW  - CHUAC
VL  - 30
ER  -